



NDA 18936/S-108
NDA 21235/S-026
NDA 21520/S-047

SUPPLEMENT APPROVAL

Eli Lilly and Company
Attention: Anindita Sen, Ph.D.
Director, Global Regulatory Affairs, US
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Sen:

Please refer to your Supplemental New Drug Application (sNDA) dated October 25, 2016, received October 25, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for (NDA 018936) Prozac (fluoxetine hydrochloride) 10 mg, 20 mg, 40mg Pulvule; (NDA 021235) Prozac Weekly (fluoxetine hydrochloride) 90 mg Delayed Release Capsules; (NDA 021520) Symbyax (olanzapine and fluoxetine HCL) Capsules, 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, and 12 mg/50 mg.

We also refer to our letter dated September 21, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for all selective serotonin reuptake inhibitor (SSRI) and serotonin and norepinephrine reuptake inhibitor (SNRI) products. This information pertains to the addition of "amphetamine" to list of serotonergic drugs which can potentially increase risk for serotonin syndrome.

These supplemental new drug applications provide for revisions to the labeling for Prozac, Prozac Weekly, and Symbyax consistent with our September 21, 2016 letter.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your October 25, 2016, submission includes final printed labeling (FPL) for your package insert, and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 18936/S-108
NDA 21235/S-026
NDA 21520/S-047
Page 3

If you have any questions, call Keith Kiedrow, Pharm.D., RAC, Senior Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, MD
Division Director
Division of Psychiatry
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
01/04/2017